Dr. Vikas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242
Summary
- Praveen Vikas, MD is an Oncologist specializing in Breast Cancer, currently practicing in Iowa City, IA. He has extensive training with a Residency in Internal Medicine and a Fellowship in Medical Oncology completed at East Tennessee State University/Quillen College of Medicine. His medical education was completed in 2002 at the N.H.L Municipal Medical College. Dr. Vikas has numerous notable publications in esteemed platforms such as The Journal of Rural Health, JAMA Oncology, and American Society of Clinical Oncology Educational Book, among others. His clinical trials focused on treatments for various conditions including Triple-Negative Breast Cancer, Stage III-IV Melanoma, Invasive Breast Cancer, Ductal Carcinoma In Situ, and Metastatic Head and Neck Squamous Cell Carcinoma.
Education & Training
East Tennessee State University/Quillen College of MedicineFellowship, Medical Oncology, 2009 - 2011- East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 2005 - 2008
N.H.L Municipal Medical CollegeClass of 2002
Certifications & Licensure
IA State Medical License 2011 - 2025
TN State Medical License 2008 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Join now to see all
Publications & Presentations
PubMed
- 635 citationsManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.Bryan J. Schneider, Jarushka Naidoo, Bianca Santomasso, Christina Lacchetti, Sherry Adkins
Journal of Clinical Oncology. 2021-11-01 - 126 citationsManagement of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.Bianca Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider
Journal of Clinical Oncology. 2021-11-01 - 27 citationsInterplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati
JAMA Oncology. 2023-01-01
Lectures
- Oncology Associated Symptoms and Individualized strategies ( OASIS): Precision symptoms management for rural patients with advanced cancer.2019 ASCO Annual Meeting - 6/1/2019
- Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety a...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
